TMCnet News
Voyager Therapeutics' TRACER™ Capsids Demonstrate Enhanced CNS Transduction Across Species; New Preclinical Results Bolster GBA1, Tau, SOD1 ALS Gene Therapy ProgramsVCAP-102 capsid achieved respective 60-fold and 50-fold improvements in brain transduction in non-human primates and mice compared to conventional AAV9 capsids with IV dosing Data demonstrate potential of multiple TRACER capsids to target CNS disorders, including certain diseases that may benefit from glial cell targeting Preclinical data demonstrate potential to ameliorate disease in models of GBA1, tauopathies, and SOD1 ALS Results presented at the American Society of Gene and Cell Therapy 25th Annual Meeting CAMBRIDGE, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today is scheduled to present new preclinical data on a family of AAV9-derived TRACER capsids demonstrating cross-species central nervous system (CNS) transduction. The Company is also scheduled to report updated results from preclinical gene therapy programs in GBA1, tauopathies, and SOD1 ALS. These results are being presented at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting in Washington, D.C. Family of AAV9-Derived Capsids Enhanced Brain Transduction Across Non-Human Primates and Mice “These TRACER findings are important because demonstrating equivalent cross-species functionality is critical to increasing a capsid’s potential for translation into humans,” said Mathieu Nonnenmacher, Ph.D., Vice President of Capsid Discovery at Voyager. “Furthermore, the glial tropism observed in this AAV9-derived capsid family may allow us to address CNS indications that would benefit from non-neuronal cell transduction.” Key Results
Additional results are scheduled to be presented today at the ASGCT Annual Meeting at 11:00 a.m. ET in Ballroom A at the Washington, D.C. Convention Center. The Company intends to make full results available on the Investor page of the Voyager website following the conclusion of the oral presentation. GBA1, Tau, and SOD1 ALS Gene Therapy Programs Ameliorate Disease in Animal Models “The positive data scheduled to be reported at ASGCT support further development of Voyager’s CNS gene therapy programs that have significant opportunity to provide patient benefit,” said Todd Carter, Ph.D., Senior Vice President of Research at Voyager. “Voyager programs for GBA1, vectorized antibodies targeting tau, and SOD1 ALS leverage our expertise across payload modalities and differentiated delivery strategies to develop genetic medicines that safely achieve therapeutic benefit in preclinical models.” GBA1
Tauopathies
The Company intends to make full results available on the Investor page of the Voyager website. SOD1 ALS
The Company intends to make full results available on the Investor page of the Voyager website. About the TRACER™ AAV Capsid Discovery Platform About Voyager Therapeutics Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. Forward-Looking Statements For example, all statements Voyager makes regarding the presentation of preclinical data at ASGCT 2022, Voyager’s ability to continue to identify and develop proprietary capsids from its TRACER AAV screening platform; Voyager’s ability to identify and develop proprietary capsids from its TRACER AAV screening platform with enhanced CNS transduction across species, increased blood-brain barrier penetration and increased biodistribution compared to conventional AAV9 capsids; Voyager’s ability to develop gene therapy approaches treating patients with Parkinson’s disease, familial amyotrophic lateral sclerosis and tauopathies; Voyager’s ability to discover AAV derived capsids with high transduction in CNS tissues via intravenous dosing in humans; Voyager’s ability to progress its research and development programs; Voyager’s ability to continue to develop preclinical data on its early pipeline programs relying upon its novel capsid discovery efforts; and Voyager’s ability to utilize its novel proprietary capsids in its product development programs are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the severity and length of the COVID-19 health crisis; the continued development of Voyager’s technology platforms, including Voyager’s TRACER platform; the ability to initiate and conduct of preclinical studies in more advanced pre-clinical animal models; the ability to attract and retain talented contractors and employees; the ability to create and protect intellectual property; and the sufficiency of cash resources. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Contacts Investors [email protected] Andrew Funderburk [email protected] Media Scott Santiamo [email protected] Peg Rusconi [email protected] |